Predicting growth of solid renal masses under active surveillance.
OBJECTIVE
The natural history and growth rates of untreated solid enhancing renal tumors is being defined through active surveillance series. Serial radiographic evaluation of patients who are not surgical candidates or refuse surgical treatment provides an opportunity to characterize the growth of untreated enhancing renal tumors. Here we evaluate factors that may help predict radiographic growth during observation.


METHODS
We reviewed our renal cancer database for enhancing renal masses that were radiographically observed for a period of at least 12 months. Variables examined included patient age, gender, lesion size on presentation, radiographic tumor characteristics, duration of active surveillance, linear growth rate, surgical pathology, development of new renal tumors, and stage progression.


RESULTS
One hundred nine patients with 124 sporadic enhancing renal tumors were identified undergoing a period of active surveillance of at least 12 months. Median patient age was 73 years (mean 69.8, range 35-87); 72% (78/109) of patients were males. Median duration of active surveillance was 26 months (mean 33.4, range 12-156). Multifocal disease was present in 9% (10/109) of patients on presentation, accounting for 20% (25/124) of all tumors. Tumor size on presentation was a median of 2.0 cm (mean 2.61, range 0.4-12.0). Overall median tumor growth rate was 0.21 cm/y (mean 0.28, range 1.4-2.47). Observed linear growth rates were independent of patient age, gender, tumor size on presentation, multifocality, and radiographic characteristics (solid versus cystic), P > 0.05. Of the patients initiating a period of active surveillance 36% (39/109) eventually underwent definitive therapy. Malignant pathology was present in 90% (35/39) of patients undergoing treatment. In patients continuing active surveillance [64% (70/109)], 2.9% (2/70) developed de novo renal lesions and 1.4% (1/70) developed metastatic disease.


CONCLUSIONS
Currently, no clinical predictors of tumor growth or disease progression have been identified, although, the risk of developing progressive disease over the short term appears low. Clinical and molecular markers of disease progression are needed prior to offering active surveillance to otherwise acceptable surgical candidates.
Crispen
Paul L
PL
Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.
Wong
Yu-Ning
YN
Greenberg
Richard E
RE
Chen
David Y T
DY
Uzzo
Robert G
RG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging* / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011859:Radiography; D012189:Retrospective Studies
J Urol. 2004 Feb;171(2 Pt 1):615-20
14713772
Urology. 2000 Jul;56(1):67-70
10869626
J Urol. 2006 Feb;175(2):425-31
16406965
Urology. 2004 Nov;64(5):909-13
15533476
Urology. 2004 Sep;64(3):462-7
15351571
J Clin Oncol. 2003 Aug 15;21(16):3133-40
12810695
N Engl J Med. 1998 Apr 30;338(18):1272-8
9562581
Urology. 2002 Sep;60(3):421-7
12350478
AJR Am J Roentgenol. 2004 Mar;182(3):551-7
14975944
Urology. 2004 Jul;64(1):49-52
15245934
J Urol. 2001 Jul;166(1):6-18
11435813
J Urol. 2007 Mar;177(3):849-53; discussion 853-4
17296355
J Urol. 2005 Mar;173(3):713-5
15711249
Urol Oncol. 2004 Sep-Oct;22(5):410-4
15464922
Radiology. 1995 Dec;197(3):589-97
7480724
Can J Urol. 2004 Oct;11(5):2407-10
15579229
J Urol. 2007 Feb;177(2):466-70; discussion 470
17222611
Semin Urol Oncol. 1995 Nov;13(4):267-72
8595550
JAMA. 1999 May 5;281(17):1628-31
10235157
J Urol. 1999 Feb;161(2):408-11
9915413
J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4
16985252
Cancer. 2004 Feb 15;100(4):738-45
14770429